Partially False: The FDA Didn't Remove All Mifepristone Screening Requirements in 2023 — Here's What Actually Changed

The claim is that the FDA removed in-person screening requirements for mifepristone in 2023, implying all oversight was stripped away. That's not what happened. The FDA made a real and significant change, but it was narrower than the claim suggests.

In January 2023, the FDA updated its rules for mifepristone to allow certified retail and mail-order pharmacies to dispense the drug. Before this, it could only be handed out at clinics, hospitals, or medical offices. That restriction is gone. KFF Health News and the Guttmacher Institute both confirmed this shift was meaningful — patients no longer have to visit a specific type of facility to pick up the medication.

But the REMS — the FDA's safety oversight program for mifepristone — was not eliminated. As the FDA itself explains, prescribers must still be specially certified to prescribe the drug, and patients must still sign a Patient Agreement Form acknowledging the risks. The American College of Obstetricians and Gynecologists also noted that these requirements remain firmly in place. Removing the in-person dispensing location rule is not the same as removing all screening.

The legal status of these changes is now settled. In June 2024, the U.S. Supreme Court unanimously ruled in FDA v. Alliance for Hippocratic Medicine that the challengers lacked legal standing to sue, leaving the FDA's updated rules intact. The 2023 changes stand — exactly as written, not as overstated.

This kind of overstatement matters because it shapes how people understand access to the medication and the level of medical oversight involved. If you see headlines saying all requirements were dropped, look for what specifically changed — the location rule — versus what stayed the same: prescriber certification and patient consent.